New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
07:56 EDTGILD, IDIX, MRKGilead weakness creates buying opportunity, says RBC Capital
After Gilead's (GILD) stock fell following Merck's (MRK) acquisition of Idenix (IDIX), RBC Capital expects Sovaldi sales to come in well above consensus estimates for 2015, potentially enabling Gilead's EPS to reach $8-$10. RBC Capital says that the market expects the sales of HCV treatments to drop significantly in 2016, but the firm does not agree with this outlook. RBC Capital keeps an Outperform rating on Gilead.
News For GILD;MRK;IDIX From The Last 14 Days
Check below for free stories on GILD;MRK;IDIX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 23, 2014
11:40 EDTGILDFDA approves Zydelig for three types of blood cancers
Subscribe for More Information
July 22, 2014
06:14 EDTGILDGilead July weekly volatility elevated into Q2
Subscribe for More Information
July 21, 2014
16:00 EDTGILDOptions Update; July 21, 2014
iPath S&P 500 VIX Short-Term Futures up 65c to 28.53. Option volume leaders: AAPL FB NFLX DG CMCSA GILD PBR TWTR TSLA according to Track Data.
09:38 EDTGILDActive equity options trading on open
Subscribe for More Information
07:21 EDTGILD, MRKGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
06:43 EDTMRK, GILDGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
12:46 EDTGILDGilead drug cocktail helps treat HIV/HCV-coinfected patients, JAMA says
Subscribe for More Information
July 17, 2014
11:12 EDTIDIXOptions with decreasing implied volatility
Subscribe for More Information
July 16, 2014
11:57 EDTGILDStocks with call strike movement; GILD YHOO
Subscribe for More Information
06:26 EDTMRKBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
11:13 EDTMRKPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
08:11 EDTMRKMerck looks to revive livestock drug Zilmax, WSJ says
Merck has been preparing to conduct a large-scale study this summer to evaluate the safety of its Zilmax feed additive, which the company pulled from the U.S. market last year over concerns in the beef industry that the drug made it difficult for some animals to walk, reported The Wall Street Journal. Reference Link
07:35 EDTMRKPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
July 14, 2014
10:00 EDTIDIXOptions with decreasing implied volatility: SHPG INFY CWH FDO IDIX FAST
09:28 EDTGILDCentene best positioned Medicaid pure play to post Q2 EPS beat, says Sterne Agee
Subscribe for More Information
July 11, 2014
15:59 EDTGILDOptions Update; July 11, 2014
iPath S&P 500 VIX Short-Term Futures down 33c to 28.25. Option volume leaders: AAPL C GILD X FB GOOG AMZN TWTR TSLA according to Track Data.
09:48 EDTGILDSenators make new request to Gilead for Sovaldi pricing details
Senate Finance Committee Chairman Ron Wyden and senior Finance Committee member Chuck Grassley made public their request for detailed pricing information on Gilead's Sovaldi, a Hepatitis C virus drug. Wyden and Grassley have asked Gilead Sciences for information about Sovaldi, a drug developed to treat and cure HCV, they disclosed, stating, “Given the impact Sovaldi’s cost will have on Medicare, Medicaid and other federal spending, we need a better understanding of how your company arrived at the price for this drug." Reference Link
07:37 EDTGILDAmerican Enterprise Institute holds a discussion
Discussion entitled, "How Will We Pay for Cost of Cures" focuses on improving the development of transformative medicines and developing financing mechanisms to pay for them and is being held in Washington, D.C. on July 11 at 8 am. Webcast Link
07:36 EDTGILDJohnson & Johnson Q2 EPS likely to exceed expectations, says Bernstein
Subscribe for More Information
July 10, 2014
16:12 EDTMRKMedivation names Dawn Svoronos as Chief Commercial Officer
Medivation (MDVN) announced Dawn Svoronos has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, CEO and president of Medivation. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co. (MRK), where she oversaw commercial operations in approximately 30 EU and EU accession countries. Svoronos will lead Medivation's commercial organization on an interim basis and will participate in the company's search for a permanent chief commercial officer. Cheryl Cohen, Medivation's former chief commercial officer, has left the company to pursue other opportunities.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use